• Download
• Corrected 9-Month Financial Report 2011
• Annual Report 2010

 

• Please learn more about our subsidiaries:
• www.heidelberg-pharma.com
  www.oncogene.com

• Meet WILEX:
• Conferences 2012 WILEX will attend

ENGLISH DEUTSCH

WILEX is a biopharmaceutical company and develops drugs based on antibodies and small molecules with a low side effect profile and targeted treatment of different types of cancer as well as diagnostic agents for specific detection of tumours. WILEX’ aim is to help oncologists administer targeted treatments to carefully diagnosed patients and to enhance patients' quality of life.

Latest News

15.02.2012: WILEX Inc. appoints Walter Carney as CSO for the further development of Oncogene Science diagnostics. WILEX Inc., a wholly owned US subsidiary of WILEX AG, today announced that Walter Carney, Ph.D., has joined the company as Chief Scientific Officer (CSO)..... (More).